News archive
Showing 644 results
November 2014
-
Media ReleaseNovartis first IL-17A Phase III results show AIN457 (secukinumab) significantly improves psoriatic arthritis in patients
-
Media ReleaseNovartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies- Exploratory analyses showed…
-
Media ReleaseNovartis AIN457 (secukinumab) showed significant symptom improvement in two pivotal Phase III ankylosing spondylitis studies
-
Media ReleaseNovartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014- Secukinumab is the first selective…
-
Media ReleaseNovartis to present first IL-17A Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
October 2014
-
Media ReleaseNovartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™Through music and resources Our Voice in Song™ inspires people living with relapsing MS to become more active managers of their diseaseInitiative launches with nationwide release of "I Can Do This,"…
-
Media ReleaseNovartis teams up with multiple sclerosis advocate and musician David Osmond to launch MS education initiative Our Voice in Song™
-
Media ReleaseNovartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015- FDA Advisory Committee…
-
Media ReleaseNovartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis
-
Media ReleaseNovartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191- Largest…
-
Media ReleaseNovartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)